



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 23rd day of July, 2003.

Kristina L. Konstas

(Signature of person mailing)
Kristina L. Konstas

(Typed or printed name of person)

TECH CENTER 1600/2900

JUL 28 2003

RECEIVED

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Harry R. Howard Jr., :

APPLICATION NO.: 10/010,651 : Examiner: Rao, Deepak R.

FILING DATE: December 6, 2001 : Group Art Unit: 1624

TITLE: COMBINATION TREATMENT FOR :
ANXIETY, DEPRESSION, OBSESSIVE
COMPULSIVE DISORDER AND
PSYCHOSIS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Sir:

COMMUNICATION IN RESPONSE TO APRIL 23, 2003 OFFICE ACTION

This Communication is being filed in response to the Office Action issued April 23, 2003 by the United States Patent and Trademark Office in connection with the above-identified patent application. A response to the April 23, 2003 Office Action was indicated thereon as being due in one month, i.e. by May 23, 2003. Applicant is filing concurrently herewith a Petition for a Two Month Extension of Time, whereby the due date for responding to the April 23, 2003 Office Action is extended to July 23, 2003. Accordingly, this Communication is being timely filed.

REMARKS

Claims 1-30 are pending in the subject application. Applicant thanks the Examiner for noting and correcting the misnumbering of the claims 1-30 as 1-31.

In the April 23, 2003 Office Action, the Examiner restricted examination of the claims of the subject application to one of the following groups of claims:

- I. Claims 1-21, directed to pharmaceutical compositions comprising a compound of formula I that exhibits activity as an SRI antidepressant and an atypical antipsychotic agent;
- II. Claims 1, 19, 20 and 21, directed to pharmaceutical compositions comprising a compound other than a compound of formula I exhibiting activity as an SRI antidepressant and an atypical antipsychotic;